Olema Oncology could be a standout player in developing therapies for girls’s cancers, particularly in breast cancer, in keeping with Citi Research. Analyst Yigal Nochomovitz initiated the clinical-stage biotech company at a buy/high risk rating, saying it has potential in developing a “next-gen endocrine therapy.” His price goal of $20 implies shares could surge more than 72% over the following 12 months. The stock was flat in trading on Tuesday, but has fallen more than 16% up to now this yr. Last yr, Olema shares soared more than 470% as the corporate released a series of positive updates, particularly about its lead investigational oncology drug palazestrant , Nochomovitz said. Palazestrant is a whole estrogen receptor antagonist, or CERAN, and selective ER degrader, or SERD, that’s currently under development for the treatment of metastatic ER+/HER2- breast cancer. The drug, which has been granted FDA “fast track,” is an oral compound, meaning it’s taken in the shape of a tablet or pill. “We imagine palazestrant has emerged as a highly promising CERAN/SERD with opportunities across multiple lines of ER+ breast cancer,” Nochomovitz wrote in a Tuesday note. “While the SERD space stays competitive and Olema is trailing the competition, we view palazestrant’s ESR1 wild-type activity, favorable combinability with CDK4/6i’s, and technique to mix with ribociclib for pivotal 1L development as possible angles for differentiation to materialize,” the analyst added. CDK4/6 inhibitors are drugs which can be used to treat metastatic breast cancer, or advanced stage IV breast cancer, which has spread to other organs within the body removed from the breast. Palazestrant has already proven it may be safely combined with the CDK 4/6 inhibitors, ribociclib and palbociclib, in a Phase 1/2 study . The corporate is trying to partner for its Phase 3 studies and Nochomovitz anticipates that shares could react once such a relationship is announced within the near to mid-term.